Logo image of WVE

WAVE LIFE SCIENCES LTD (WVE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:WVE - SG9999014716 - Common Stock

14.83 USD
-0.6 (-3.89%)
Last: 1/8/2026, 8:15:36 PM
15.16 USD
+0.33 (+2.23%)
After Hours: 1/8/2026, 8:15:36 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to WVE. WVE was compared to 191 industry peers in the Pharmaceuticals industry. While WVE has a great health rating, there are worries on its profitability. WVE shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

WVE had negative earnings in the past year.
In the past year WVE has reported a negative cash flow from operations.
WVE had negative earnings in each of the past 5 years.
In the past 5 years WVE always reported negative operating cash flow.
WVE Yearly Net Income VS EBIT VS OCF VS FCFWVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -50.62%, WVE is not doing good in the industry: 62.83% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -92.42%, WVE is doing worse than 60.21% of the companies in the same industry.
Industry RankSector Rank
ROA -50.62%
ROE -92.42%
ROIC N/A
ROA(3y)-53.06%
ROA(5y)-54.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WVE Yearly ROA, ROE, ROICWVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for WVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WVE Yearly Profit, Operating, Gross MarginsWVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

7

2. Health

2.1 Basic Checks

WVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
WVE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, WVE has more shares outstanding
There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
WVE Yearly Shares OutstandingWVE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
WVE Yearly Total Debt VS Total AssetsWVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 5.49 indicates that WVE is not in any danger for bankruptcy at the moment.
WVE's Altman-Z score of 5.49 is fine compared to the rest of the industry. WVE outperforms 73.82% of its industry peers.
There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.49
ROIC/WACCN/A
WACC9.46%
WVE Yearly LT Debt VS Equity VS FCFWVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

WVE has a Current Ratio of 2.50. This indicates that WVE is financially healthy and has no problem in meeting its short term obligations.
WVE's Current ratio of 2.50 is in line compared to the rest of the industry. WVE outperforms 45.55% of its industry peers.
A Quick Ratio of 2.50 indicates that WVE has no problem at all paying its short term obligations.
The Quick ratio of WVE (2.50) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.5
Quick Ratio 2.5
WVE Yearly Current Assets VS Current LiabilitesWVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.43% over the past year.
Looking at the last year, WVE shows a very strong growth in Revenue. The Revenue has grown by 103.75%.
The Revenue has been growing by 46.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)32.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.91%
Revenue 1Y (TTM)103.75%
Revenue growth 3Y38.28%
Revenue growth 5Y46.63%
Sales Q2Q%199.11%

3.2 Future

Based on estimates for the next years, WVE will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.44% on average per year.
The Revenue is expected to grow by 44.62% on average over the next years. This is a very strong growth
EPS Next Y-52.05%
EPS Next 2Y-26.65%
EPS Next 3Y-10.7%
EPS Next 5Y17.44%
Revenue Next Year-20.29%
Revenue Next 2Y-3.84%
Revenue Next 3Y28.73%
Revenue Next 5Y44.62%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
WVE Yearly Revenue VS EstimatesWVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
WVE Yearly EPS VS EstimatesWVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

WVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year WVE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WVE Price Earnings VS Forward Price EarningsWVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WVE Per share dataWVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

WVE's earnings are expected to decrease with -10.70% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.65%
EPS Next 3Y-10.7%

More info and screens

0

5. Dividend

5.1 Amount

WVE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

WAVE LIFE SCIENCES LTD

NASDAQ:WVE (1/8/2026, 8:15:36 PM)

After market: 15.16 +0.33 (+2.23%)

14.83

-0.6 (-3.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners78.92%
Inst Owner Change0%
Ins Owners0.37%
Ins Owner Change-1.99%
Market Cap2.48B
Revenue(TTM)109.23M
Net Income(TTM)-122.00M
Analysts84
Price Target32.7 (120.5%)
Short Float %10.34%
Short Ratio1.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.92%
Min EPS beat(2)-6.2%
Max EPS beat(2)-5.63%
EPS beat(4)1
Avg EPS beat(4)42.65%
Min EPS beat(4)-10.05%
Max EPS beat(4)192.48%
EPS beat(8)2
Avg EPS beat(8)13.75%
EPS beat(12)4
Avg EPS beat(12)-24.39%
EPS beat(16)5
Avg EPS beat(16)-19.89%
Revenue beat(2)0
Avg Revenue beat(2)-24.9%
Min Revenue beat(2)-32.32%
Max Revenue beat(2)-17.49%
Revenue beat(4)1
Avg Revenue beat(4)30.06%
Min Revenue beat(4)-32.32%
Max Revenue beat(4)195.76%
Revenue beat(8)2
Avg Revenue beat(8)-5.69%
Revenue beat(12)4
Avg Revenue beat(12)7.93%
Revenue beat(16)4
Avg Revenue beat(16)-14.72%
PT rev (1m)60.82%
PT rev (3m)63.23%
EPS NQ rev (1m)-0.95%
EPS NQ rev (3m)-3.16%
EPS NY rev (1m)0.74%
EPS NY rev (3m)-2.84%
Revenue NQ rev (1m)4.39%
Revenue NQ rev (3m)-10.39%
Revenue NY rev (1m)1.88%
Revenue NY rev (3m)-10.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.7
P/FCF N/A
P/OCF N/A
P/B 18.78
P/tB 18.78
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-1.27
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0.65
BVpS0.79
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.62%
ROE -92.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.06%
ROA(5y)-54.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.08%
Cap/Sales 0.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.5
Quick Ratio 2.5
Altman-Z 5.49
F-Score4
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)22.4%
Cap/Depr(5y)18.24%
Cap/Sales(3y)13.04%
Cap/Sales(5y)9.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.91%
EPS Next Y-52.05%
EPS Next 2Y-26.65%
EPS Next 3Y-10.7%
EPS Next 5Y17.44%
Revenue 1Y (TTM)103.75%
Revenue growth 3Y38.28%
Revenue growth 5Y46.63%
Sales Q2Q%199.11%
Revenue Next Year-20.29%
Revenue Next 2Y-3.84%
Revenue Next 3Y28.73%
Revenue Next 5Y44.62%
EBIT growth 1Y10.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.96%
EBIT Next 3Y-14.69%
EBIT Next 5YN/A
FCF growth 1Y-865.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-908.66%
OCF growth 3YN/A
OCF growth 5YN/A

WAVE LIFE SCIENCES LTD / WVE FAQ

What is the ChartMill fundamental rating of WAVE LIFE SCIENCES LTD (WVE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to WVE.


What is the valuation status for WVE stock?

ChartMill assigns a valuation rating of 0 / 10 to WAVE LIFE SCIENCES LTD (WVE). This can be considered as Overvalued.


How profitable is WAVE LIFE SCIENCES LTD (WVE) stock?

WAVE LIFE SCIENCES LTD (WVE) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for WVE stock?

The Earnings per Share (EPS) of WAVE LIFE SCIENCES LTD (WVE) is expected to decline by -52.05% in the next year.